Raymond James raised the firm’s price target on Abbott (ABT) to $142 from $132 and keeps an Outperform rating on the shares. The firm says underlying Q1 results were solid and the reiteration of 2025 EPS guidance, despite 17c of incremental tariff expense, is encouraging. A weaker USD provides an offset to the tariffs, but the guide highlights the cushion in the model. Q1 represents the second straight quarter of high-single organic revenue/double-digit EPS growth, and the Q2 guidance implies another quarter with this growth algorithm, Raymond James adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target raised to $145 from $133 at Piper Sandler
- Abbott Laboratories: Strong Performance and Strategic Positioning Drive Buy Rating
- Abbott price target raised to $145 from $135 at Stifel
- Abbott Laboratories: Strong Growth and Resilience Justify Buy Rating
- Abbott price target raised to $147 from $136 at Wells Fargo